Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 phase 3 study in generalized pustular psoriasis or erythrodermic psoriasis
jRCT2031230714Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of zasocitinib in generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP) (2 arms), sponsored by Takeda. Primary endpoints: Percentage of participants achieving sPGA clear or almost clear with at least 2-point decrease from baseline at Week 16 and Percentage of participants achieving PASI-75 at Week 16. Started Mar 2024; status: completed.
02
Drugs
zasocitinib
03
Conditions
generalized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on jRCT2031230714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230714.